About seller
e needed to improve the visibility and viewer experience of accurate healthcare content on social media. J Drugs Dermatol. 2021;20(6)623-629. doi10.36849/JDD.5835.The original article “The Skin Health and Beauty Pyramid” was published in 2014. In the last 7 years, many new skin care innovations have been developed that were not available at the time of the first publication. New mechanisms of action for recently identified unmet skin aging needs along with novel ingredients have been commercialized that warrant the attention of dermatologists, skin care professionals, and patients. This article updates the original pyramid with these new concepts. J Drugs Dermatol. 2021;20(6)695-699. doi10.36849/JDD.5883 THIS ARTICLE HAD BEEN MADE AVAILABLE FREE OF CHARGE. PLEASE SCROLL DOWN TO ACCESS THE FULL fTEXT OF THIS ARTICLE WITHOUT LOGGING IN. NO PURCHASE NECESSARY. PLEASE CONTACT THE PUBLISHER WITH ANY QUESTIONS. Hair care products can be comedogenic, and therefore contribute to acne. Subasumstat mw Hair care products can leave a residue on the skin, even with rinse off products. This residue may explain why hair care products can cause acne. 27 subjects aged 16–45 with mild to moderate facial and truncal acne utilized a non-comedogenic hair care regimen for 8 weeks. Dermatologist assessment of acne severity was performed with the PGA (truncal acne) and IGA (facial acne) scale at baseline and 8 weeks. At 8 weeks 70% of subjects with truncal acne showed improvement in PGA, and 52% of subjects with facial acne showed improvement in IGA by dermatologist grading. Subject self-assessment corresponded with dermatologist grading, with 74% agreeing that their skin looks and feels healthier at 8 weeks. This non-comedogenic hair care regimen showed efficacy in improving mild to moderate truncal and facial acne, both by dermatologist grading and subject self-assessment. Hair care products should be considered as a possible contributor to acne. J Drugs Dermatol. 2021;20(6)690-693. doi10.36849/JDD.5772.This non-comedogenic hair care regimen showed efficacy in improving mild to moderate truncal and facial acne, both by dermatologist grading and subject self-assessment. Hair care products should be considered as a possible contributor to acne. J Drugs Dermatol. 2021;20(6)690-693. doi10.36849/JDD.5772. Reddit, the seventh most visited website in the United States, has become an exceedingly popular platform for patients to source medical information and discuss chronic conditions. To uncover patient questions regarding atopic dermatitis, as physicians can use this knowledge to better address patient concerns and more comprehensively educate patients. The authors analyzed 1,000 questions posted on the “Hot” section of the “eczema” subreddit. Each question was then separated into categories and subcategories for analysis. 1,000 questions from 881 posts were analyzed. The highest proportion of questions (29.5%) were non-pharmacologic management focused, with patients inquiring about diet, over the counter skincare products, personal hygiene practices, clothing, and supplements. Non-specific management (19.1%), uncertainty about symptoms (14.6%), medications (14.3%), cause and triggers (10.3%), and mental health (6.9%) were common categories as well. The questions of the eczema subreddit subscribers may not reflect the questions of all atopic dermatitis patients. This analysis demonstrates that atopic dermatitis patients require greater management guidance, especially non-pharmacologic strategies, and more comprehensive discussions regarding the range of symptoms, trigger avoidance, and mental health resources. Addressing these gaps in knowledge may lead to improved outcomes and more informed, empowered patients. J Drugs Dermatol. 2021;20(6)653-658. doi10.36849/JDD.5734Visit the Atopic Dermatitis Resource Center.This analysis demonstrates that atopic dermatitis patients require greater management guidance, especially non-pharmacologic strategies, and more comprehensive discussions regarding the range of symptoms, trigger avoidance, and mental health resources. Addressing these gaps in knowledge may lead to improved outcomes and more informed, empowered patients. J Drugs Dermatol. 2021;20(6)653-658. doi10.36849/JDD.5734Visit the Atopic Dermatitis Resource Center. The Food and Drug Administration (FDA) recommends grading Acne vulgaris via an Investigator’s Global Assessment (IGA) scale and assessing treatment as either success or failure, with success defined as clear (grade 0) or almost clear (grade 1) with at least a two-grade improvement in acne severity from baseline. To determine the likelihood of achieving real world treatment success in patients with acne according to FDA guidance. We calculated estimated appropriates to obtain the IGA 0/1 (clear or almost clear rate) for many of the oral and topical medications. We also used the National Ambulatory Medical Care Survey (NAMCS) data to determine the number of medications prescribed for outpatient visits when isotretinoin was prescribed or when isotretinoin was not prescribed and the one and only diagnosis was acne. Isotretinoin had the highest IGA 0/1 at 87%. None of the other medications had an IGA 0/1 > 40%. Of all outpatient acne visits, only 6% receive isotretinoin. When excluding isotretinoin visits, 71% of patients received ≤ 2 medications. The majority of the acne medication studies lasted 12 weeks, however, it can take 6 months or longer to get the maximum effect. None of the studies combined topical and oral medications. The majority of acne patients are not likely to achieve success according to FDA guidance. We propose that the FDA guidance may be too rigorous. An alternative hypothesis is that most acne patients are undertreated. J Drugs Dermatol. 2021;20(6)648-651. doi10.36849/JDD.5727.The majority of acne patients are not likely to achieve success according to FDA guidance. We propose that the FDA guidance may be too rigorous. An alternative hypothesis is that most acne patients are undertreated. J Drugs Dermatol. 2021;20(6)648-651. doi10.36849/JDD.5727.